# Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Source: https://onco.cc/trials/nct06301386/  
OnCo record `nct06301386` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of everolimus in colorectal cancer, run by Fudan University, not yet recruiting.

## Summary

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients is a phase 2, interventional study registered as NCT06301386 by Fudan University, with a registry enrolment figure of 25 participants, started 2024-04-01 and due to reach its primary completion in 2026-05-01. Interventions recorded: Everolimus; PD-1. Conditions listed: Colon Cancer. Primary outcome: objective response rate (ORR). Colorectal eligibility wording from the registry: "Patients with histologically or cytologically confirmed locally advanced and advanced colorectal cancer that cannot be R0 resected;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06301386
- Phase: 2
- Setting: The Combination of Everolimus and PD-1 in the Treatment of Locally Advanced and Advanced Colorectal Cancer That Cannot be R0 Resected
- Sponsor: Fudan University
- Enrolled: 25

## Sources

- ClinicalTrials.gov NCT06301386: https://clinicaltrials.gov/study/NCT06301386

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- drugs: [Everolimus](https://onco.cc/drugs/everolimus/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06301386.json